Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LSPN925
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
LSPN925 is an experimental **coumarin-dihydropyrimidinone hybrid** small molecule reported in a 2025 medicinal chemistry study as an in vitro anticancer lead for ovarian cancer research. In that publication, it emerged as one of the more active synthesized compounds in a panel of cancer cell assays and was further evaluated for effects on cell morphology and colony formation. Its precise validated molecular target and mechanism of action were not disclosed in the provided source, so it is best described at present as a preclinical cytotoxic antineoplastic research compound rather than a clinically developed drug candidate.
Beyond the preview
Go deeper on LSPN925.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LSPN925.